SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED

Shandong Xinhua Pharmaceutical Company Limited

719 CNE100000411

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 01:38:25 16/01/2026 pm IST			5-day change	1st Jan Change
6.900 ^HKD	-0.29%		-0.58%	+4.70%

29/12	Shandong Xinhua Pharmaceutical says valsartan capsules obtained drug registration certificate from NMPA	RE
29/12	Shandong Xinhua Pharmaceutical Company Limited Receives Drug Registration Certificate in Connection with Its Phloroglucinol Injection	CI

Shandong Xinhua Pharmaceutical Gets China Supplementary Approval for Epinephrine Hydrochloride Injection; Shares Fall 3%

Published on 11/28/2025 at 11:12 am IST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Shandong Xinhua Pharmaceutical Company Limited

29/12	Shandong Xinhua Pharmaceutical says valsartan capsules obtained drug registration certificate from NMPA	RE
29/12	Shandong Xinhua Pharmaceutical Company Limited Receives Drug Registration Certificate in Connection with Its Phloroglucinol Injection	CI
29/12	Shandong Xinhua Pharmaceutical Company Limited Receives Drug Registration Certificate in Connection with Its Valsartan Capsules	CI
23/12	Xinhua Pharmaceutical Gets Registration Certificate for Influenza Drug in China	MT
23/12	Shandong Xinhua Pharmaceutical Company Limited Receives Drug Registration Certificate in Connection with Its Oseltamivir Phosphate for Suspension	CI
28/11	Shandong Xinhua Pharmaceutical Gets China Approval for Prednisolone Acetate Raw Material	MT
28/11	Shandong Xinhua Pharmaceutical Gets China Supplementary Approval for Epinephrine Hydrochloride Injection; Shares Fall 3%	MT
27/11	Xinhua Pharmaceutical Gets China Nod for Inflammatory Disease Drug-Related Marketing	MT
27/11	Xinhua Pharmaceutical's Dyspnea Drug Passes Chinese Regulator's Consistency Evaluation	MT
27/11	Shandong Xinhua Pharmaceutical Company Limited Obtains Notification of Approval of Marketing Application for Chemical Active Pharmaceutical Ingredients	CI
27/11	Shandong Xinhua Pharmaceutical Company Limited Announces Epinephrine Hydrochloride Injection Passes Generics Consistency Evaluation	CI
26/11	Shandong Xinhua Pharmaceutical Gets China Nod for Lidocaine Cream; Shares Rise 5%	MT
25/11	Xinhua Pharmaceutical Obtains Registration Certificate for Local Skin Anesthesia Drug	MT
25/11	Shandong Xinhua Pharmaceutical Company Limited Receives Drug Registration Certificate in Connection with Its Lidocaine and Prilocaine Cream	CI
18/11	Shandong Xinhua Pharmaceutical Gets China Marketing Nod for Reflux Esophagitis Drug	MT
31/25/31	Xinhua Pharmaceutical Gets Registration Certificate for Osteoporosis Drug	MT
31/25/31	Shandong Xinhua pharmaceutical received drug registration certificate for alendronate sodium oral solution	RE
31/25/31	Shandong Xinhua Pharmaceutical Company Limited Receives Drug Registration Certificate in Connection with Its Alendronate Sodium Oral Solution	CI
27/25/27	Shandong Xinhua Pharma Renews Trademark Licence with Hualu; Shares Down 3%	MT
24/25/24	Shandong Xinhua Pharmaceutical Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
24/25/24	Xinhua Pharmaceutical's Profit Slips 26% in Q1-Q3	MT
14/25/14	Shandong Xinhua Pharmaceutical Gets Regulatory Nod for Cardiovascular Drug	MT
13/25/13	Xinhua Pharmaceutical Gets Registration Certificate for Heart Disease Drug in China	MT
13/25/13	Shandong Xinhua Pharmaceutical Company Limited Receives Drug Registration Certificate in Connection with its Bisoprolol Fumarate Tablets	CI
25/25/25	Xinhua Pharmaceutical Gets Trial Approval for Hypertension Drug in China	MT

Chart Shandong Xinhua Pharmaceutical Company Limited

Duration

Period

Chart Shandong Xinhua Pharmaceutical Company Limited

719: Dynamic Chart

SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED is a China-based company principally engaged in the development, production and distribution of chemical bulk drugs, preparations and medical intermediates. The Companyâs main products include metamizole sodium, caffeine, aminopyrine, aspirin, hydrocortisone, pipemidic acid, ibuprofen, L-dopa, pipemidic acid tablets, compound liquorice tablets and nimodipine tablets. The Company distributes its products in domestic market and to overseas markets, including the Americas, Europe and others.

Employees

7,296

Sector

Pharmaceuticals

Calendar

30/03 - Q4 2025 Earnings Release

More about the company